[Clinical studies on cefuzonam in obstetric and gynecological infections]. 1987

H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
Department of Obstetrics and Gynecology, School of Medicine, Teikyo University.

Seventeen patients with gynecological infections (5 cases each of Bartholin's abscess and adnexitis, 4 cases of endometritis and 1 case each of bartholinitis, pyosalpinx and vulvar abscess) were treated with cefuzonam (CZON, L-105) administered by intravenous drip infusion, 1-2 g twice daily, for 4 to 12 days (6 g to 23 g in total). The clinical effectiveness reached 94.1%, including 1 excellent case, 15 cases good, and a poor case. Bacteria were detected in 9 cases, and with CZON treatment, bacterial eradications were obtained in 6 case, but, in 3 cases, bacterial replacements were observed. No abnormal laboratory findings were noted. From the above results, CZON seemed to be a highly effective and useful agent for gynecological infections.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D005831 Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). Gynecologic Diseases,Female Genital Diseases,Diseases, Female Genital,Diseases, Gynecologic,Female Genital Disease,Genital Disease, Female,Gynecologic Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D015296 Ceftizoxime A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. Ceftizoxime Sodium,Cefizox,Ceftizoxime Monosodium Salt,FK-749,FK749,FR-13749,SK&F 88373-2,SKF-88373,FK 749,FR 13749,FR13749,Monosodium Salt, Ceftizoxime,SK&F 88373 2,SK&F 883732,SKF 88373,SKF88373,Salt, Ceftizoxime Monosodium,Sodium, Ceftizoxime

Related Publications

H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
May 1987, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
October 1987, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
May 1987, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
August 1968, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
May 1987, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
October 1986, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
February 1987, The Japanese journal of antibiotics,
H Iwase, and M Uno, and T Tsujii, and H Ikeshita, and M Hogaki, and K Arai
March 1987, The Japanese journal of antibiotics,
Copied contents to your clipboard!